期刊文献+

深静脉血栓形成模型大鼠股静脉内皮组织中核转录因子kappa B1和组织因子的表达(英文) 被引量:3

Expression of nuclear factor kappa B1 and tissue factor in femoral venous endothelial tissue of the rat deep vein thrombosis model
下载PDF
导出
摘要 背景:目前调控静脉内皮细胞、血小板、炎性细胞之间相互作用,促进局部深静脉血栓微环境形成的机制尚不完全清楚,仍未发现早期诊断深静脉血栓的可靠方法。目的:研究核转录因子kappaB1和组织因子在大鼠深静脉血栓形成中的作用。方法:将67只SD大鼠随机分为对照组和模型组,对模型组采用股静脉钳夹联合下肢石膏制动构建大鼠深静脉血栓形成模型。于造模后2.5,25h,解剖股静脉观测血栓的发生情况,进一步将模型组分为:血栓形成前组(造模后2.5h)、血栓形成组和血栓不形成组(造模后25h)。取各组股静脉内皮组织,采用基因芯片筛查差异表达的基因,并进一步采用real-timePCR进行验证。结果与结论:基因芯片分析及real-timePCR结果均发现,造模后2.5h,血栓形成前组大鼠股静脉内皮组织中核转录因子kappaB1和组织因子表达明显高于对照组(P<0.05);造模后25h,血栓形成组大鼠股静脉内皮组织中核转录因子kappaB1和组织因子表达明显高于血栓形成前组、血栓不形成组和对照组(P<0.05)。提示局部静脉内皮组织中核转录因子kappaB1和组织因子表达水平上调可能在深静脉血栓形成中发挥了重要作用。 BACKGROUND:At present,the basic underlying molecular mechanism regulating the interactions among venous endothelial cells,platelets,leukocytes,and promoting local deep vein thrombosis microenvironment formation,still remains unclear,and there is no ideal method for early diagnosis of deep vein thrombosis.OBJECTIVE:To study the underlying role of nuclear factor kappa B1 and tissue factor in rats with deep vein thrombosis.METHODS:A total of 67 Sprague-Dawley rats were randomly divided into control group(n=10) and model group(n=57).Deep vein thrombosis model was established by a clamping and sewing method in femoral vein combined with cast fixation.The incidence and serious degree of thrombus were observed by dissecting rat femoral vein in different time points(2.5 and 25 hours after modeling).The model group was further divided into pre-thrombogenesis group(2.5 hours after modeling),thrombogenesis group(25 hours after modeling) and non-thrombogenesis group(25 hours after modeling).Then total RNA was extracted from the localized femoral venous endothelial tissue.The candidate genes,associated inflammation and thrombosis,were screened by a special gene chip.Then the gene expression of nuclear factor kappa B1 and tissue factor was further identified by real-time polymerase chain reaction.RESULTS AND CONCLUSION:Pre-thrombogenesis group had no thrombogenesis,while thrombogenesis group have 23 cases with thrombosis and non-thrombogenesis group have 22 cases without thrombosis.The results of gene chip hybridization analysis and real-time PCR found that the mRNA expression of nuclear factor kappa B1 and tissue factor in rat femoral vein endothelial tissue were significantly up-regulated at 2.5 hours after modeling(pre-thrombogenesis group was higher than control group)(P 0.05),and continued up-regulating at 25 hours after modeling(thrombogenesis group was higher than the pre-thrombogenesis group,non-thrombogenesis group and control group)(P 0.05).The results from present study indicate that up-regulating expressions of nuclear factor kappa B1 and tissue factor in local femoral venous endothelial tissue of rat deep vein thrombosis models may play a key role in initiating venous thrombosis.
出处 《中国组织工程研究》 CAS CSCD 2012年第7期1245-1250,共6页 Chinese Journal of Tissue Engineering Research
基金 the National Natural Science Foundation of China,No.30960389,81060151,81160236 Joint Funds of Yunnan Sci-Tech Department and Kunming Medical College,No.2009cd159 Yunnan New Key Product Development Projects,No.2010BC010 Doctor Innovation Foundation of Kunming Medical College,No.2011D07~~
  • 相关文献

参考文献3

二级参考文献4

共引文献79

同被引文献50

  • 1徐波,张彩英,冼碧霞.急性脑梗死患者纤溶酶原激活剂抑制物-1活性及其基因启动子区域4G/5G基因多态性研究[J].中国医师进修杂志,2006,29(5):26-28. 被引量:2
  • 2Zangari M, Fink L, Zhan F, et al. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens. Clin Lymphoma Myeloma Leuk , 2011,11 (2): 228-236.
  • 3Mullen E, Mendez N. Hyperviscosity syndrome in patients with multiple myeloma. Oncol Nurs Forum,2008,35(3) :350-352.
  • 4Elice F, Fink L, Tricot G, et al. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol.2006.134(4) :399-405.
  • 5Musallam KM. Dahdaleh FS. Shamseddine AI, et al. Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy. Thromb Res.2009.123(5):679-686.
  • 6Zangari M. Berne T. Zhan F. et al. Mechanisms of thrombosis in paraprot einernias , the effects of immunomodulatory drugs. Semin Thromb Hemost.2012.38(8) :768-779.
  • 7Zamagni E. Brioli A. Tacchetti P. et al. Multiple myeloma. venous thromboembolism. and treatment-related risk of thrombosis. Semin Thromb Hemost.2011.37(3) :209-219.
  • 8Anaissie EJ, Coleman EA. Goodwin JA. et al. Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis. Cancer. 2012.118(2):549-557.
  • 9Sperry BW. Roskos M. Oskoui R. The effect of laterality on venous thromboembolism formation after peripherally inserted central catheter placement. J Vase Access.2012.13(1) :91-95.
  • 10Avcu F. Ural AU. Cetin T, et al. Effects of bortezomib on platelet aggregation and ATP release in human platelets. in vitro. Thromb Res.2008.121(4) :567-571.

引证文献3

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部